Obesity lab: India becomes ground zero for weight-loss drug race
Remove Ads
Innovator drugs enter the Indian market
Tired of too many ads?
Remove Ads
Popular in Healthcare/Biotech
1.
Mind your posture: Doctors cite long hours in front of screen for increasing lifestyle diseases
Tired of too many ads?
Remove Ads
Generic tsunami looms as patents near expiry
Indian pharma prepares to scale up
Cipla signals intent to join the fray
Government support and 'Make in India' for global export
India's escalating obesity crisis
Market projections and challenges ahead
India is rapidly transforming into a crucial focal point for the global weight management industry, serving as both a significant market for novel anti-obesity drugs and a burgeoning hub for the production of their more affordable generic versions.This dual role is driven by an escalating obesity crisis within the country, coupled with the impending patent expirations of blockbuster weight loss medications and robust government incentives.Global pharmaceutical giants like Novo Nordisk have recently launched Wegovy, intensifying competition with Eli Lilly's Mounjaro which debuted earlier this year, while Indian pharmaceutical companies such as Dr. Reddy's, Sun Pharma, Cipla, Biocon, and Lupin are actively developing their own generic versions, aiming for market entry as early as 2026 once key patents expire.Global pharmaceutical giants have recognised India's significant market potential, launching their advanced anti-obesity medications.Eli Lilly & Co. launched its anti-obesity drug, Mounjaro (Tirzepatide), in India in March 2025. The company introduced the drug in a single-dose vial after receiving marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).According to data compiled by Pharmarack, Mounjaro recorded sales of nearly ₹24 crore in its first three months (March–May). More recent data from ET indicates Mounjaro's usage doubled in June, with sales value growing by 18% to ₹50 crore for that month alone.The Economic Times reported that a 2.5 mg vial of Mounjaro is priced at ₹3,500, and a 5 mg vial at ₹4,375, translating to ₹14,000–17,500 per month depending on weekly dose. A six-month treatment could cost about ₹1 lakh.Sales of 2.5 mg injections rose to ₹5.08 crore in May from ₹4.80 crore in April and ₹1.42 crore in March, when it was launched, according to PharmaTrac data.Danish firm Novo Nordisk also launched its anti-obesity drug, Wegovy (Semaglutide 2.4 mg), in major Indian cities on June 24. Originally planned for 2026, Novo Nordisk advanced Wegovy's launch to mid-2025 to directly challenge Mounjaro and capitalise on rising demand.Wegovy is available in five dose strengths in India. The 0.25 mg, 0.5 mg, and 1 mg versions are priced at ₹4,336.25. The monthly cost would be ₹17,345, similar to Mounjaro. The 1.7 mg dose is priced at ₹24,280, and the 2.4 mg version at ₹26,015 for a month's supply.India's growing middle and upper-middle classes can afford higher-cost treatments, making the country attractive to drug innovators. For example, Eli Lilly's Mounjaro, priced between ₹14,000–17,500 per month, has already seen significant uptake.Novo Nordisk's oral semaglutide drug, Rybelsus, launched in January 2022, has grown from ₹26 crore to ₹412 crore, commanding a two-thirds share of the GLP-1 market.Eli Lilly's tirzepatide-based Mounjaro, introduced in March 2025, clocked ₹50 crore in sales within its first quarter, capturing 8% of the market. Unit sales jumped from 11,637 in March to nearly 88,000 by June, nearly half of which were the 2.5 mg starter dose, indicating high patient onboarding and adherence.Novo Nordisk's injectable Wegovy, launched in late June 2025, sold 1,788 units worth ₹2.53 crore across five dosage strengths, likely driven by patients previously using imported versions.India's middle and upper-middle classes are now not just ablea to afford premium treatments: they're willing to. A once-unthinkable ₹15,000/month drug like Mounjaro is gaining real traction. That's not just a signal of rising income, it's a shift in mindset: people are prioritising preventive and lifestyle healthcare.Novo Nordisk's Rybelsus growing 15x in two years shows this isn't a one-off. It's a trend. And with Mounjaro hitting ₹50 crore in just one quarter, the demand for GLP-1s, whether for diabetes or weight loss, is real and scaling fast.High uptake of low starter doses also suggests something else: these aren't just prescriptions handed out to a few elite patients. Doctors are onboarding a lot of new users, and those users are sticking with the meds, at least through the early stages.For the right kind of innovative drugs, especially in chronic lifestyle conditions, it's becoming a viable, profitable market even at global price points.The landscape of weight management drugs in India is poised for a significant shift with the impending patent expirations of Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications used for both type 2 diabetes and obesity.Key patents for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, are set to expire around January 2026 in some regions and sometime next year in India. This "patent cliff" is a major catalyst for Indian generic manufacturers and Indian pharmaceutical companies are readying to bring in a range of generic versions of Novo Nordisk's semaglutide.The move could open up cheaper access to weight-loss and diabetes drugs, possibly setting off a generics boom worth billions.Novo Nordisk's semaglutide franchise generated $17 billion from Ozempic and $8.4 billion from Wegovy in 2024 alone, as per the company's 2024 annual financial results.Patents for semaglutide are expected to lapse in over 100 countries, including Canada (January 2026), Brazil (March 2026), and India.Now, major Indian players, including Dr. Reddy's, Biocon, Sun Pharma, Cipla, Lupin, and Aurobindo Pharma, are positioning themselves strategically.Bengaluru-based OneSource Specialty Pharma is investing $100 million to scale up production, anticipating a revenue jump to $400 million within three years. Neeraj Sharma, CEO of OneSource, said in a media interview, 'Semaglutide will be a big part of it,' citing growing demand.Dr. Reddy's CFO MV Narasimham stated that the company is ready for a "high-volume, low-cost" market and has end-to-end capabilities, as reported by Moneycontrol. Dr. Reddy's, which has been developing semaglutide for over a decade, is preparing for a global rollout, including injectable and oral formulations.Biocon Chairperson Kiran Mazumdar-Shaw called the opportunity "very huge," noting the company's unique portfolio of GLP-1s and insulins. Biocon has already launched oral GLP-1 diabetes drug Liraglutide in the UK.Biocon received CDSCO approval for its generic Liraglutide substance and product on June 2. It was also the first generic Liraglutide approved in the UK (March 2024), launched in February 2025, and approved in the EU (December 2024), demonstrating India's capability in complex peptide manufacturing.Zydus Lifesciences is investing over ₹100 crore ($12 million) in a new manufacturing facility using proprietary technology to produce cost-effective semaglutide, as per Moneycontrol.Hyderabad-based Divi's Laboratories, a key supplier of semaglutide components, has reported strong growth in its peptide business amid rising global demand, with HSBC projecting it to generate around $450 million in revenue from peptides by 2030.Cipla, a major Indian drug firm, is actively preparing to enter the weight management segment in India. As reported by PTI on July 13, Umang Vohra, Cipla's MD and Global CEO, stated in the company's Annual Report for 2024-25, 'Obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions.'Cipla's consolidated revenue stood at ₹27,548 crore in FY25, with a net profit of ₹5,272 crore.The Indian government is actively supporting domestic pharmaceutical manufacturing through its Production-Linked Incentive (PLI) scheme. With an outlay of ₹1.97 lakh crore across 14 sectors, the scheme aims to boost the production of complex drugs, including Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs), as per the Press Information Bureau.In 2024-25, the government disbursed ₹10,114 crore under the PLI schemes, with pharmaceutical drugs receiving ₹2,328 crore, as reported by ET.Further, specific incentives for GLP-1 receptor agonists under the PLI framework are anticipated. Bloomberg reported on June 28 last year that Arunish Chawla, secretary with the Department of Pharmaceuticals, confirmed a PLI scheme for drugs used in the treatment of obesity and diabetes would be introduced in 2026. This aims to support domestic production of GLP-1 drugs.This government backing, combined with patent expirations, is intended to position India not just as a domestic supplier but also as a major global exporter of affordable generic GLP-1s.India is grappling with a rapidly increasing prevalence of overweight and obesity, impacting not just adults but children as well. According to the World Health Organization (WHO), almost half of all children under five who were overweight or living with obesity in 2024 resided in Asia — underscoring the regional impact.India's status as the 'Diabetes Capital of the World,' with 77 million adults living with diabetes (WHO), runs parallel with the obesity epidemic.A 2024 study published in the International Journal of Research and Review found that 29.7% of children aged 6–12 in Lucknow were overweight or obese, nearly three times the national average of 8.4%. This early trend of metabolic dysfunction provides a key 'laboratory' for studying disease progression and treatment responses.The global market for GLP-1-based weight loss drugs is projected to more than triple over the next six years, rising from $13.84 billion in 2024 to $48.84 billion by 2030, growing at a CAGR of 18.5%, according to Grand View Research.India's growth trajectory is even sharper. The domestic GLP-1 receptor agonist market, valued at $110.55 million in 2024, is expected to grow at a 34.3% CAGR from 2025 to 2030 — nearly twice the global rate. This growth is driven by rising cases of type 2 diabetes and obesity, increased R&D, patent expiries, and the expected entry of generics.According to the International Diabetes Federation's 2024 report, nearly 9 million Indian adults are currently at risk of diabetes. That figure could rise to 185 million by 2050, as projected by Grand View Research.This rising disease burden is already reshaping India's pharmaceutical market. PharmaTrac data shows the anti-obesity drug market in India reached ₹628 crore as of June 2025, a fivefold increase over five years, driven by GLP-1 drugs like semaglutide and tirzepatide. With a 46% CAGR, this is now the fastest-growing therapeutic segment in the Indian pharma space. GLP-1s account for 75% of the market by value.Despite booming demand, manufacturing GLP-1 drugs remains technically challenging. These peptide-based therapies require advanced facilities, significant investment, and specialised expertise. Delivery devices like injection pens add further complexity to the supply chain.Legal battles are already unfolding. In May, Novo Nordisk sued Dr. Reddy's and OneSource Specialty in Delhi High Court, seeking to block domestic sales of their semaglutide generics. For now, Indian companies can continue to manufacture and export the drug.Still, the global potential is massive. Goldman Sachs now estimates the anti-obesity drug market could hit $95 billion by 2030.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
6 minutes ago
- Hindustan Times
Cardiologist says eating okra helps maintain blood pressure, diabetes; lists 6 benefits of the vegetable
In an Instagram post shared on July 27, Dr Alok Chopra, cardiologist and functional medicine expert, talked about a very simple Indian vegetable found in every household: okra, also known as bhindi or lady finger. He listed the benefits of eating this vegetable, including supporting heart health, and also shared why you should add okra water to your diet. Bhindi or okra is more than just a staple in Indian kitchens — it's a powerhouse of nutrition. Also Read | Cardiologist says 'heart attacks are no longer #1 killer in the US' but this silent trend is claiming more lives Benefits of eating okra Apart from heart health benefits, the cardiologist pointed out that this humble green vegetable could also be your gut's best friend and offer several other benefits. He wrote, 'Bhindi or okra is more than just a staple in Indian kitchens — it's a powerhouse of nutrition. And when soaked overnight, its slimy water turns into a potent remedy. It's affordable, widely available, and found in every Indian household, whether you are in a metro city or a small town.' Listing the benefits of eating okra, Dr Chopra said: It regulates blood sugar It is excellent for type 2 diabetes It supports digestion, hydration, and metabolism It helps in weight loss due to its high fibre content It helps maintain blood pressure while supporting heart health. Lastly, it protects the stomach lining, making it great for healing peptic ulcers. Okra for diabetes management Further elaborating on how okra helps in diabetes management, Dr Chopra said that studies have suggested that consuming up to 1000 mcg of okra every 6 hours for 8 weeks can have a significant impact on HbA1c and sugar reduction. Why should you drink okra water? Apart from having okra as a vegetable dish, another way to include it in your diet is by having okra water. Here's how you make okra water: Take 2-3 fresh okra pods, wash them thoroughly, cut off the ends, and make small slits. Soak them in a glass of water overnight, strain the water, and drink it in the morning on an empty stomach. How does it help? 'The fibre-rich drink slows digestion, prevents sugar spikes, and supports gut health. However, in some cases, excess fibre may cause bloating or mild stomach discomfort, so consult a doctor if you have any concerns, but this is not common. Okra water also enhances metabolism, but metabolism is not just about burning calories; it's about how your body processes energy. Factors like poor diet, stress, and lack of sleep can slow it down, while strength training, protein intake, and hydration can naturally boost it,' the cardiologist explained. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Time of India
3 hours ago
- Time of India
Hovering over the toilet? You may be hurting your bladder
New Delhi: Hovering over public toilets to avoid germs may seem hygienic, but doctors warn it can harm your bladder. The half-squat position often adopted by women prevents full bladder emptying, increasing the risk of urine retention, urinary tract infections (UTIs) and long-term pelvic floor issues. "It causes increased bladder pressure and can raise the risk of UTIs, bladder irritation, and even long-term problems," said Dr Nikhil Khattar, associate director, urology, PSRI Hospital. He explained that when this posture is used regularly, it trains the body into a habit of incomplete urination. This affects how the bladder muscles function, and may eventually cause symptoms like frequent urgency, leakage or difficulty emptying the bladder fully. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi "Retained urine also provides a good environment for bacteria to grow, which increases the chance of recurrent UTIs and, in some cases, even kidney infections," he said. The risks are similar when people delay urinating for too long, which many do in public places to avoid using unclean restrooms. "Whether you are holding your urine or not sitting properly while passing it, both habits harm the pelvic floor muscles and interfere with normal bladder emptying," Dr Khattar added. Dr Neelam Suri, senior consultant in obstetrics and gynaecology at Indraprastha Apollo Hospitals, said the full squat position — as used with traditional Indian toilets — is much healthier. "In a full squat, the pelvic muscles relax fully, making it easier to empty both the bladder and bowel," she said. "Half-squatting or hovering keeps the muscles tense and doesn't allow proper urination." According to her, many women hover over Western-style toilets out of fear of infection. But the posture itself can do more harm in the long run. "Studies suggest that hovering increases the risk of incomplete urination and pelvic strain, which can lead to chronic issues," she added. Dr Gaurav Garg, senior consultant, urology, Max Smart Hospital, Saket, also said long-term half-squatting can contribute to pelvic floor dysfunction and stress incontinence — where urine leaks out during coughing, sneezing or physical activity. "Many women who come to us with these issues don't realise it's linked to their posture during urination," he said. Doctors also clarified a common myth: simply sitting on a public toilet seat doesn't directly cause UTIs. "UTIs are primarily caused by bacteria like E. coli entering the urethra and multiplying in the urinary tract," said Dr Khattar. "Poor hygiene, improper wiping, touching contaminated surfaces or not washing hands properly are bigger risks. The toilet seat itself is rarely the cause." D r Atul Goswami, director of urology and uro-oncology at Sri Balaji Action Medical Institute, said awareness is key and women should feel empowered to sit properly by using tools like disposable seat covers or toilet seat sanitisers when using public toilets. "Touching the seat is not as dangerous as incomplete urination, which can cause real and lasting harm," he said. Experts stressed the need to educate women about proper toilet habits and break the widespread fear around public toilet seats. "We must spread the message that sitting properly and emptying the bladder fully is essential for good urinary health," said Dr Suri. In a country where access to clean public toilets remains a challenge, doctors say small changes — like carrying hygiene products and choosing to sit instead of hover — can help protect long-term health. What feels like a quick fix may be doing silent damage, and the best choice might just be the one that feels most uncomfortable: sitting down.
Time of India
4 hours ago
- Time of India
53% of Indian Youths Are ‘Personality Malnourished': Study
1 2 Nagpur: India is often called a young country, with nearly 26 crore people between the ages of 18 and 29. This is seen as our greatest strength. However, a new study brings serious concern — 53% of Indian youth are 'personality malnourished'. This means their overall growth as individuals is not happening well — they are missing important life skills, emotional strength, and social values, the study found. This study was conducted by Amrut Bang, project director of NIRMAN, who presented three research papers at the Emerging Adulthood Conference held in Charleston, USA, recently. NIRMAN is a youth educational initiative started under Gadchiroli-based NGO SEARCH (Society for Education, Action, Research in Community Health). Bang's key paper is based on research involving 4,283 young people between 2021 and 2024. The conference focused on the life phase of Emerging Adulthood (18 to 29 years) — a time when young people explore their identity and build their future. The term was introduced by psychologist Jeffrey Arnett, who also attended the conference with over 300 researchers from across the world. "The National Education Policy 2020 calls for the complete, all-round development of youth. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Where Your Search Ends Hotel Deals | Search Ads Browse Now Undo NIRMAN has developed a way to measure this overall growth," said Bang. "Our research clearly shows that more than half of Indian youth are malnourished in their personality. This is a big concern that needs attention." He added, "While 35% of Indian children are physically malnourished, 53% of youth are personality malnourished. This is an even bigger problem." There were 50 questions in total. If a youth scored poorly in two-thirds (2/3) of the questions in any one area, they were considered personality malnourished in that domain. The study found that 53% of youth were personality malnourished in four or more areas. Only 9% showed good growth in all seven important areas of life. "We have tools to check if a child is growing well physically. In the same way, we need tools to check if our youth are growing well as people. That's why we created this method," said Bang. # How is Personality Malnourishment Measured? NIRMAN developed a simple method to check the overall growth of youth in seven important life areas: - Physical health - Mental health - Character and values - Relationships - Professional growth - Life skills - Social contribution More Insights Amrut Bang also presented two more studies: - The Emotional World of Indian Youth: A study on the most common emotions experienced by Indian youth - The Questions Indian Youth Are Asking: Based on 6,100 real questions from young people. The most frequently asked question: 'Who am I, and what is the purpose of my life?'
